Significantly improved UPSIT score vs placebo at Weeks 24 and 52 (secondary endpoints)1
Change in upsIt score through week 52 in trial 2
at Week 52 with DUPIXENT (baseline score 13.46) vs 6% worsening with placebo (baseline score 13.78) (LSM difference: 10.30 [95% CI: 8.50, 12.10])
- DUPIXENT 300 mg Q2W + INCS (n=150)
- Placebo + INCS (n=153)
OF THE TOTAL IMPROVEMENT IN SENSE OF SMELL WAS SEEN AFTER THE FIRST DOSE, AS MEASURED AT WEEK 21,a
- aChange in UPSIT score at Week 2 (LSM difference vs placebo: 5.36 [95% CI: 3.62, 7.10]).1
REDUCTION IN THE NUMBER OF PATIENTS WITH ANOSMIA1,2
- 79% (n=228/287, pooled DUPIXENT arms) of patients taking DUPIXENT 300 mg Q2W + INCS had
anosmia at baseline, which was reduced to 30% (n=84/280, pooled
DUPIXENT arms) at Week 24 in Trial 21,2
- There was almost no change with placebo: 76.7% (n=115/150 total patients) of patients taking placebo + INCS had anosmia at baseline, which was reduced to 76.6% (n=111/145 total patients) at Week 24 in Trial 21,2
- 46% IMPROVEMENT IN DAILY LOSS OF SMELL SCORE AT WEEK 52 (Trial 2: secondary endpoint) with DUPIXENT 300 mg Q2W + INCS (n=150) (-1.29 from a baseline score of 2.81) vs 7% improvement with placebo + INCS (n=153) (-0.19 from a baseline score of 2.72) (LSM difference: -1.10 [95% CI: -1.31, -0.89])1
- University of Pennsylvania Smell Identification Test (UPSIT) score (range 0 to 40): higher score indicates improvement.
- INCS, intranasal corticosteroids; LSM, least squares mean; Q2W, once every 2 weeks.